Mid-term transcripts of 126 pharmaceutical companies!

The mid-term transcripts of pharmaceutical and biological companies are emerging

Specifically, there are 86 companies with anticipated performance increase, accounting for nearly 70%.

It is worth noting that there are still 15 companies whose performance is expected to decline.

Chemical medicine 

Resuming market growth boosts performance

Downturn in raw material drug prices hits overseas business hard

In order to broaden its own development path in the medical equipment and cosmetics sector, Harbin Sanlian increased its capital to Fuerjia Technology with 100% equity of its wholly-owned subsidiary Beixing Pharmaceutical in February this year, and obtained this domestic medical sodium hyaluronate facial dressing market development.

However, the substantial growth of Jinshiya Pharmaceutical's net profit relies on the performance contribution made by its leading products

With the effective control of the domestic epidemic, the production and sales of enterprises are as usual.

traditional Chinese medicine 

Spin-off of pharmaceutical e-commerce, investment profit exceeds 700 million

Non-main business brings top two increase in net profit

Looking at this list of TOP10 net profit growth forecasts for the Chinese medicine sector, the first thing that comes into view is Tai'antang, which has a net profit of more than 500 million yuan and a year-on-year increase of nearly 20 times

  Qizheng Tibetan Medicine, which has a net profit growth cap of more than 1 billion yuan, also stands out on this list

  Comparing the reasons for the changes in the performance of the two pharmaceutical companies, Tai'antang and Qizheng Tibetan Medicine, the traditional Chinese medicine companies focusing on their main business and deep-growing industries are obviously more pragmatic

Biological product

Overall performance is mixed

The pipeline is abundant, and I am worried about entering the medical insurance

  Specifically, Palin Biotechnology ranks first with a 200% increase in net profit.

  Anke Bio, which has continued to strengthen its marketing efforts and improved its sales channels, has also allowed its main product, recombinant human growth hormone, to achieve substantial year-on-year growth, thereby driving the growth of its consolidated net profit indicator
.
From the industry's perspective, with the recent approval of new indications for human growth hormone for injection, Anke Bio will continue to be the main profit point in the future
.
However, the news that the Guangdong-led Super Centralized Procurement Alliance intends to incorporate recombinant human growth hormone has once lowered the stock prices of related companies such as Changchun Hi-tech and Anke Biology.
Will this unresolved challenge bring a greater impact to Anke Biology? Performance impact remains to be observed
.
  

  It should be noted that there are still 8 biopharmaceutical companies experiencing pre-decline or pre-loss
.
Among them, Sihuan Bio, whose net profit has dropped by as much as 538.
33%, is clearly the focus of attention in the industry
.
Sihuan Biologics attributed its own performance loss to the year-on-year decline in the performance of its holding subsidiary Beijing Sihuan Biopharmaceuticals, and the disposal of its wholly-owned subsidiary Guangxi Intercontinental Forestry Investment Equity, resulting in a year-on-year decline in income from timber forest business
.
It is worth intriguing that Sihuan Biotech has made clear that its development strategy is based on biomedicine manufacturing, and at the same time develops ecological agriculture and forestry industry as a new profit growth point.
However, the biomedical sector has continued to be sluggish in recent years.
The net profit was 3.
0113 million yuan, while the Guangxi Intercontinental Forestry Investment realized a net profit of 36.
96 million yuan, which was a difference of more than 10 times.
The business results of turning the cart before the horse are not known for how long Sihuan Biological can stay in the field of biomedicine
.
  

  Based on the characteristics of high inherent technical risk, long R&D cycle, and large capital investment in the field of biomedicine research and development, it has a rich pipeline of biopharmaceutical products, but Biotech, which only launched adalimumab, still gave a judgment on the pre-loss performance
.
Sansheng Guojian, which gave the same performance forecast, believes that as the number of competing products included in the medical insurance coverage increases and the price of competing products has been reduced, the market competition for its key product Yisaipu has intensified.
After entering the medical insurance catalog, there are risks such as uncertainty in performance
.
  

medical instruments

The explosive growth of foreign trade orders

Procurement of consumables with volume shows its power

  The medical device field is currently the main force in the disclosure of interim performance forecasts.
There are as many as 39 companies, and it is also a segment of companies with the highest net profit and net profit growth
.
On the whole, including Leadman and Toujing Life, two companies that are expected to turn around, a total of 28 companies including Thermoview Biotechnology, Haohaishengke, and Jiuqiang Biotechnology have achieved positive growth in their performance, accounting for more than 70% of the total.
; There are still 10 companies such as Sino Medical, Jiu'an Medical, and Baolight that have predicted a substantial decline in performance or pre-loss or reduce losses
.
  

  Among them, Hotview Biotechnology takes the highest profit growth rate as high as 81808.
47%
.
Affected by the continuous development of the new crown epidemic in Europe and the world in the first half of the year, the foreign trade orders for two new coronavirus antigen rapid detection reagent products under Hotview Bio have exploded, which prompted a substantial increase in its operating performance in the first half of the year, and finally generated a net profit increase.
A gratifying result of over 80,000%
.
Coincidentally, Oriental Bio, which has a net profit increase limit of more than 500% and a growth limit of 3.
53 billion yuan, also relies on its new coronavirus antigen rapid detection test paper (colloidal gold) to continue to invest in the global new crown epidemic prevention and control business
.
  

  In addition to the factors that contributed to the explosive growth of performance in the overseas fight against the epidemic, the recovery of domestic market demand and the initiative of companies to adjust business strategies are also the main reasons.
Haohaishengke, Aojing Medical, Leadman, Huitai Medical, etc.
By continuing to carry out various marketing and marketing activities, expand brand awareness and influence, so as to achieve a greater increase in product sales; and in terms of innovation in play, Dean Diagnostics firmly strengthens the unique competitive advantage of integrated medical diagnosis solutions and vigorously Promote the special inspection business based on the precision center and the general inspection business that uses cooperation and joint construction as value-added; Wanfu Biologics conforms to the industry trend driven by disease types and application scenarios, and organizes the domestic marketing department Reform, to promote the coordinated development of various business lines through personnel integration and channel reuse
.
  

  With the price and volume of protective products returning to normal at this stage, compared with the same period last year due to the surge in demand for anti-epidemic materials, which led to a larger sales revenue and profit base, companies such as Jiu'an Medical, Ogilvy Medical, and Yangpu Medical have all given performance A notice of a sharp drop
.
In addition, the high-volume procurement policy from the pharmaceutical field is subverting the competitive landscape in the field of high-value consumables
.
Due to the non-selection of national coronary stents, Sino Medical’s product sales dropped by 85.
61% compared with the same period last year, and revenue decreased by 124 million yuan, a year-on-year decrease of 90.
01%
.
In explaining the main reason for the decline in net profit, Sino Medical stated that due to the sharp decline in the sales of coronary stent products, the scale effect of its products has decreased, and the production cost of its products has not decreased in proportion to that
.
    

Conclusion <<<

Industrial policies such as volume purchases and medical insurance catalog adjustments have all been normalized, and encouraging innovation is obviously the main guideline
.
With the further improvement of regulatory policies and capital market systems, domestic innovative drugs will gradually return to rationality.
In the future, only pharmaceutical companies with truly innovative attributes will stand out.
Pseudo-innovation and backward pharmaceutical production capacity will gradually be marginalized or even fade out of the industry’s sight.
The established local innovation ecosystem opens the era of internationalization
.